Victory Capital Management Inc. increased its position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 38.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,116 shares of the company's stock after acquiring an additional 17,310 shares during the period. Victory Capital Management Inc. owned about 0.11% of Astrana Health worth $1,959,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of ASTH. KBC Group NV acquired a new position in Astrana Health in the 3rd quarter worth about $70,000. Quarry LP acquired a new position in Astrana Health in the third quarter worth approximately $77,000. Quest Partners LLC bought a new position in Astrana Health during the third quarter valued at approximately $133,000. US Bancorp DE lifted its stake in Astrana Health by 3,880.0% in the fourth quarter. US Bancorp DE now owns 4,776 shares of the company's stock valued at $151,000 after acquiring an additional 4,656 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in Astrana Health in the third quarter worth approximately $220,000. Institutional investors and hedge funds own 52.77% of the company's stock.
Astrana Health Stock Performance
NASDAQ ASTH traded up $0.06 during trading on Friday, hitting $30.88. The company's stock had a trading volume of 236,026 shares, compared to its average volume of 254,224. Astrana Health, Inc. has a 52 week low of $23.12 and a 52 week high of $63.20. The firm has a market cap of $1.74 billion, a P/E ratio of 23.75, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The firm has a 50 day moving average price of $33.95 and a 200 day moving average price of $42.67. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.
Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $665.21 million for the quarter, compared to the consensus estimate of $617.24 million. Equities research analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on ASTH shares. Truist Financial cut their price target on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a report on Tuesday. Stifel Nicolaus cut their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Bank of America decreased their price target on Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Macquarie raised Astrana Health to a "hold" rating in a research note on Monday, December 16th. Finally, Robert W. Baird decreased their target price on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of "Moderate Buy" and an average price target of $56.17.
Get Our Latest Stock Report on Astrana Health
About Astrana Health
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
See Also
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
